PCSK9 and Hypercholesterolemia: A second target patient population for VERVE-201 is refractory hypercholesterolemia, as occurs in patients with atherosclerotic cardiovascular disease who fail to achieve adequate LDL-C reduction to protect from recurrent events even after use of oral therapies and a PCSK9 inhibitor.